Latest Breaking News On - Abdulkader puranwala - Page 1 : comparemela.com

JB Chemicals looks to double revenue with expansion in the domestic market

JB Chemicals looks to double revenue with expansion in the domestic market
businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.

South africaAbdulkader puranwalaContract developmentManufacturing organisationPharmaceuticals ltdContract manufacturing operations

Sun Pharma net up 16 5% at ₹2,524 crore on robust sales

Sun Pharmaceutical Industries Ltd reported a consolidated net profit of ₹2,523.75 crore, up 16.5% y-o-y, supported by robust sales, volume growth, and new product launches.

Dilip shanghviAbdulkader puranwalaSun pharmaceutical industries ltdTaro pharmaceuticalsSecurities ltdSun pharmaceutical industriesQ3 results

Sun Pharma s Move To Fully Acquire Taro Is A Good Proposition, Say Analysts

Sun Pharmaceutical Industries Ltd.'s definitive merger agreement to fully acquire Taro Pharmaceutical Industries Ltd. is a good proposition that adds value for the Indian drugmaker, according to analysts. Sun Pharma, which owns 78.48% of Taro currently, has agreed to acquire all of the outstanding ordinary shares of Taro not currently held by it.

Vishal manchandaAbdulkader puranwalaSun pharmaSystematix corporate services ltdSecurities ltdSystematix corporate servicesSun pharmaceutical industries ltdShare priceNifty pharma

After API subsidiary sale, Glenmark aims to check R&D spends, expand margins

The company’s R&D expenditure will come down to 7-7.5 percent of sales after the disinvestment in Glenmark Lifesciences. It was virtually double, at 14.2 percent of sales, in FY 17-18

Abdulkader puranwalaGlenmark lifesciencesParam desaiGlen saldhanaSun pharmaGlenmark pharmaSun pharmaceuticalsSenior research analyst at prabhudas lilladherGlenmark pharmaceuticalsGlenmark life sciences for rsGlenmark life sciencesAssistant vice presidentNew chemical entitySenior research analystGlenmark lifesciences

glenmark: Glenmark closes 3% lower post API arm sale deal

According to analysts, the sale of Glenmark Life could impact the profitability of Glenmark Pharma in FY25 but lower interest payments could offset the impact. ICICI Securities said the company will use the proceeds to clear its outstanding debt of 4,340 crore as of FY23 but the transaction is likely to result in an earnings cut of 5% for FY25. The brokerage has a sell rating on the stock with a price target of 660.

Tushar manudhaneRohan johnGlenmark pharmaAashita jainKunal randeriaAbdulkader puranwalaGlenmark pharmaceuticalsGlenmark life sciencesMotilal oswal financial servicesGlenmark lifeApi arm